Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML)
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in…
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in…
Results of Pivotal Phase 2 Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Results of Pivotal Phase 2 Trial of Tagraxofusp (SL-401) in Patients with…
CD123+ plasmacytoid dendritic cells (pDCs) from systemic sclerosis patients are susceptible to the cytotoxic activity of tagraxofusp, a CD123-targeted therapy
CD123+ plasmacytoid dendritic cells (pDCs) from systemic sclerosis patients are…
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML)
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in…
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in…
Interim Results from a Phase 1 Trial of SL-801, a Novel XPO1 Inhibitor, in Patients with Advanced Solid Tumors
Interim Results from a Phase 1 Trial of SL-801, a Novel XPO1 Inhibitor, in…
Evaluation of Combination Tagraxofusp (SL-401) and Hypomethylating Agent (HMA) Therapy for the Treatment of Chronic Myelomonocytic Leukemia (CMML). ASH 2018.
Evaluation of Combination Tagraxofusp (SL-401) and Hypomethylating Agent (HMA)…